IP Library Granted Patent US 7,041,131
Granted Patent B2
US 7,041,131 · App. 10/411,816 · Granted May 9, 2006

Bioengineered vascular graft support prostheses

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,041,131
App. No.
10/411,816
Granted
May 9, 2006
Kind
B2
Abstract

The invention is directed to bioengineered vascular graft support prostheses prepared from cleaned tissue material derived from animal sources. The bioengineered graft prostheses of the invention are prepared using methods that preserve cell compatibility, strength, and bioremodelability of the processed tissue matrix. The bioengineered graft prostheses are used for implantation, repair, or for use in a mammalian host.

Claims (32)

1. A method for implanting a collagen tube as an external support for a grafted blood vessel comprising:

(a) performing a first anastomosis of the blood vessel graft to the host blood vessel;

(b) passing the blood vessel graft through a collagen tube; and

(c) performing a second anastomosis of the blood vessel graft to the host blood vessel;

wherein the collagen tube comprises at least one layer of processed tissue matrix derived from tunica submucosa of the small intestine, wherein the processed tissue matrix comprises mechanically cleaned and chemically cleaned collagenous tissue, and wherein the external blood vessel support is bioremodelable when implanted into a host.

2. The method of claim 1 , further comprising completely covering the blood vessel graft, including both anastomoses, with the collagen tube.

3. The method of claim 1 , wherein the collagenous tissue is chemically cleaned by a process comprising:

(a) contacting the collagenous tissue with a chelating agent under alkaline conditions;

(b) contacting the collagenous tissue with an acid containing a salt;

(c) contacting the collagenous tissue with a buffered salt solution; and

(d) rinsing the collagenous tissue.

4. The method of claim 1 , wherein the processed tissue matrix comprises less than about 5% dry weight glycoproteins, glycosaminoglycans, proteoglycans, lipids, non-collagenous proteins and nucleic acids.

5. The method of claim 1 , wherein the processed tissue matrix is substantially free of cells and cellular debris.

6. The method of claim 1 , wherein the tunica submucosa of the small intestine is porcine.

7. The method of claim 1 , wherein the external blood vessel support covers the blood vessel graft.

8. The method of claim 7 , wherein the external blood vessel support completely covers the blood vessel graft.

9. The method of claim 7 , wherein the grafted blood vessel comprises two anastomoses and wherein the external blood vessel support covers both anastomoses.

10. The method of claim 7 , wherein the external blood vessel support of the blood vessel graft modulates tyrosine kinase signaling in the blood vessel graft.

11. The method of claim 7 , wherein the external blood vessel support of the blood vessel graft reduces tyrosine kinase activity in the blood vessel graft.

12. The method of claim 7 , wherein the external blood vessel support of the blood vessel graft modulates the hyperplastic response in the blood vessel graft.

13. The method of claim 7 , wherein the external blood vessel support of the blood vessel graft increases shear stress in the blood vessel graft.

14. The method of claim 7 , wherein the external blood vessel support of the blood vessel graft reduces wall tension in the blood vessel graft.

15. The method of claim 7 , wherein the external blood vessel support of the blood vessel graft preserves smooth muscle cell function in the blood vessel graft.

16. The method of claim 7 , wherein the blood vessel graft recovers endothelial-dependent relaxation with the external blood vessel support.

17. The method of claim 1 , wherein the processed tissue matrix is physically and/or chemically modified.

18. The method of claim 1 , wherein the collagen tube comprises about 10 layers or less.

19. The method of claim 1 , wherein the collagen tube is crosslinked by contacting it with a chemical crosslinking agent that preserves bioremodelability.

20. The method of claim 19 , wherein the crosslinking agent comprises a solution of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride.

21. The method of claim 1 , wherein the layer of processed tissue matrix overlaps itself an additional percentage of the circumference of the tube to form a bonding region.

22. The method of claim 21 , wherein the additional percentage of overlap is between about 5% to about 20% of the circumference of the tube.

23. The method of claim 1 , wherein the collagen tube comprises about 2 to about 6 layers of processed tissue matrix derived from tunica submucosa of the small intestine, and wherein a layer of processed tissue matrix overlaps itself an additional percentage of about 5% to about 20% of the circumference of the tube to form a bonding region.

24. The method of claim 1 , further comprising securing the ends of the collagen tube.

Assignments (5)
TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT Recorded Aug 6, 2021
From: ORGANOGENESIS INC.
To: SILICON VALLEY BANK
Reel/Frame 057112/0677 →
SECURITY INTEREST Recorded Jun 19, 2018
From: ORGANOGENESIS INC.
To: SILICON VALLEY BANK
Reel/Frame 046392/0242 →
RELEASE OF SECURITY INTEREST Recorded Mar 23, 2017
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: ORGANOGENESIS INC.
Reel/Frame 042072/0977 →
SECURITY AGREEMENT Recorded Sep 23, 2011
From: ORGANOGENESIS, INC.
To: WELLS FARGO BANK, N.A.
Reel/Frame 026954/0666 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2003
From: ABRAHAM, GINGER A.; CARR, ROBERT M. JR.; HUYNH, TAM; HAGEN, PER OTTO; DAVIES, MARK
To: ORGANOGENESIS INC.; DUKE UNIVERSITY SCHOOL OF MEDICINE
Reel/Frame 013976/0194 →